Literature DB >> 24145039

Misregulation of pre-mRNA alternative splicing in cancer.

Jian Zhang1, James L Manley.   

Abstract

UNLABELLED: Alternative splicing of mRNA precursors enables one gene to produce multiple protein isoforms with differing functions. Under normal conditions, this mechanism is tightly regulated in order for the human genome to generate proteomic diversity sufficient for the functional requirements of complex tissues. When deregulated, however, cancer cells take advantage of this mechanism to produce aberrant proteins with added, deleted, or altered functional domains that contribute to tumorigenesis. Here, we discuss aspects of alternative splicing misregulation in cancer, focusing on splicing events affected by deregulation of regulatory splicing factors and also recent studies identifying mutated components of the splicing machinery. SIGNIFICANCE: An increasing body of evidence indicates that aberrant splicing of mRNA precursors leads to production of aberrant proteins that contribute to tumorigenesis. Recent studies show that alterations in cellular concentrations of regulatory splicing factors and mutations in components of the core splicing machinery provide major mechanisms of misregulation of mRNA splicing in cancer. A better understanding of this misregulation will potentially reveal a group of novel drug targets for therapeutic intervention. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145039      PMCID: PMC3823817          DOI: 10.1158/2159-8290.CD-13-0253

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  102 in total

Review 1.  The SR protein family of splicing factors: master regulators of gene expression.

Authors:  Jennifer C Long; Javier F Caceres
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

Review 2.  IFNgamma signaling-does it mean JAK-STAT?

Authors:  Daniel J Gough; David E Levy; Ricky W Johnstone; Christopher J Clarke
Journal:  Cytokine Growth Factor Rev       Date:  2008-10-16       Impact factor: 7.638

3.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.

Authors:  Qun Pan; Ofer Shai; Leo J Lee; Brendan J Frey; Benjamin J Blencowe
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

4.  Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.

Authors:  Saurabh Dayal; Alison Sparks; Jimmy Jacob; Nerea Allende-Vega; David P Lane; Mark K Saville
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

5.  Functional and evolutionary insights into human brain development through global transcriptome analysis.

Authors:  Matthew B Johnson; Yuka Imamura Kawasawa; Christopher E Mason; Zeljka Krsnik; Giovanni Coppola; Darko Bogdanović; Daniel H Geschwind; Shrikant M Mane; Matthew W State; Nenad Sestan
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

6.  Identification of alternative splicing markers for breast cancer.

Authors:  Julian P Venables; Roscoe Klinck; Anne Bramard; Lyna Inkel; Geneviève Dufresne-Martin; ChuShin Koh; Julien Gervais-Bird; Elvy Lapointe; Ulrike Froehlich; Mathieu Durand; Daniel Gendron; Jean-Philippe Brosseau; Philippe Thibault; Jean-Francois Lucier; Karine Tremblay; Panagiotis Prinos; Raymund J Wellinger; Benoit Chabot; Claudine Rancourt; Sherif Abou Elela
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

7.  Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

Authors:  Maike Buchner; Simon Fuchs; Gabriele Prinz; Dietmar Pfeifer; Kilian Bartholomé; Meike Burger; Nina Chevalier; Laurent Vallat; Jens Timmer; John G Gribben; Hassan Jumaa; Hendrik Veelken; Christine Dierks; Katja Zirlik
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

8.  A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis.

Authors:  Chunjiang He; Fang Zhou; Zhixiang Zuo; Hanhua Cheng; Rongjia Zhou
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

Review 9.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

10.  Alternative isoform regulation in human tissue transcriptomes.

Authors:  Eric T Wang; Rickard Sandberg; Shujun Luo; Irina Khrebtukova; Lu Zhang; Christine Mayr; Stephen F Kingsmore; Gary P Schroth; Christopher B Burge
Journal:  Nature       Date:  2008-11-27       Impact factor: 49.962

View more
  150 in total

Review 1.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

2.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

Authors:  Teng Fei; Yiwen Chen; Tengfei Xiao; Wei Li; Laura Cato; Peng Zhang; Maura B Cotter; Michaela Bowden; Rosina T Lis; Shuang G Zhao; Qiu Wu; Felix Y Feng; Massimo Loda; Housheng Hansen He; X Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-13       Impact factor: 11.205

3.  Mechanism of alternative splicing and its regulation.

Authors:  Yan Wang; Jing Liu; B O Huang; Yan-Mei Xu; Jing Li; Lin-Feng Huang; Jin Lin; Jing Zhang; Qing-Hua Min; Wei-Ming Yang; Xiao-Zhong Wang
Journal:  Biomed Rep       Date:  2014-12-17

Review 4.  Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Authors:  Diego M Marzese; Ayla O Manughian-Peter; Javier I J Orozco; Dave S B Hoon
Journal:  Clin Exp Metastasis       Date:  2018-05-29       Impact factor: 5.150

Review 5.  Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.

Authors:  Charlotte K Brierley; David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 6.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

Review 7.  Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation.

Authors:  Yongsheng Li; Daniel J McGrail; Juan Xu; Gordon B Mills; Nidhi Sahni; Song Yi
Journal:  Trends Biochem Sci       Date:  2018-06-22       Impact factor: 13.807

Review 8.  A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.

Authors:  Gilbert S Omenn; Yuanfang Guan; Rajasree Menon
Journal:  J Proteomics       Date:  2014-05-05       Impact factor: 4.044

9.  The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.

Authors:  Guillermo Aldave; Marisol Gonzalez-Huarriz; Angel Rubio; Juan Pablo Romero; Datta Ravi; Belén Miñana; Mar Cuadrado-Tejedor; Ana García-Osta; Roeland Verhaak; Enric Xipell; Naiara Martinez-Vélez; Arlet Acanda de la Rocha; Montserrat Puigdelloses; Marc García-Moure; Miguel Marigil; Jaime Gállego Pérez-Larraya; Oskar Marín-Bejar; Maite Huarte; Maria Stella Carro; Roberto Ferrarese; Cristobal Belda-Iniesta; Angel Ayuso; Ricardo Prat-Acín; Fernando Pastor; Ricardo Díez-Valle; Sonia Tejada; Marta M Alonso
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

10.  Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Authors:  S T Workenhe; T Ketela; J Moffat; B P Cuddington; K L Mossman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.